A Phase 1 Open-Label Study of the Safety Tolerability and Efficacy of KPT-9274 A Dual Inhibitor of PAK4 and NAMPT in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma (PANAMA)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors And Nhl
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patient must have advanced solid malignancies or non-Hodgkin lymphoma for which all standard therapeutic options considered useful have been exhausted

     

    2.  Patient must have a site of disease amenable to biopsy

     

    3.  Patient must have objective evidence of progressive disease


You may not be eligible for this study if the following are true:

  • 1.  Pregnancy or lactation

     

    2.  Known, active Hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg

     

    3.  Patients with significantly decreased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea that could interfere with the absorption of KPT-9274




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.